DEXCOM INC (DC4.DE) Stock Fundamental Analysis
FRA:DC4 - Deutsche Boerse Ag - US2521311074 - Common Stock - Currency: EUR
Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 58 industry peers in the Health Care Equipment & Supplies industry. DC4 has an excellent profitability rating, but there are some minor concerns on its financial health. DC4 is valued quite expensive, but it does show an excellent growth. These ratings would make DC4 suitable for growth investing!
1. Profitability
1.1 Basic Checks
DC4 had positive earnings in the past year.
DC4 had a positive operating cash flow in the past year.
Each year in the past 5 years DC4 has been profitable.
DC4 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.93%, DC4 belongs to the top of the industry, outperforming 82.76% of the companies in the same industry.
With an excellent Return On Equity value of 23.61%, DC4 belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
DC4's Return On Invested Capital of 14.54% is amongst the best of the industry. DC4 outperforms 94.83% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is above the industry average of 8.02%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.54%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.93% | ||
| ROE | 23.61% | ||
| ROIC | 14.54% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
With a decent Profit Margin value of 12.90%, DC4 is doing good in the industry, outperforming 79.31% of the companies in the same industry.
In the last couple of years the Profit Margin of DC4 has grown nicely.
Looking at the Operating Margin, with a value of 16.54%, DC4 is in the better half of the industry, outperforming 77.59% of the companies in the same industry.
In the last couple of years the Operating Margin of DC4 has grown nicely.
DC4 has a Gross Margin (60.72%) which is in line with its industry peers.
In the last couple of years the Gross Margin of DC4 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.54% | ||
| PM (TTM) | 12.9% | ||
| GM | 60.72% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DC4 is creating some value.
DC4 has more shares outstanding than it did 1 year ago.
DC4 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DC4 has an improved debt to assets ratio.
2.2 Solvency
DC4 has an Altman-Z score of 6.12. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DC4 (6.12) is better than 87.93% of its industry peers.
DC4 has a debt to FCF ratio of 4.35. This is a neutral value as DC4 would need 4.35 years to pay back of all of its debts.
DC4 has a Debt to FCF ratio of 4.35. This is in the better half of the industry: DC4 outperforms 65.52% of its industry peers.
A Debt/Equity ratio of 0.57 indicates that DC4 is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.57, DC4 is doing worse than 63.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 6.12 |
ROIC/WACC1.76
WACC8.25%
2.3 Liquidity
A Current Ratio of 1.50 indicates that DC4 should not have too much problems paying its short term obligations.
DC4 has a Current ratio of 1.50. This is comparable to the rest of the industry: DC4 outperforms 44.83% of its industry peers.
DC4 has a Quick Ratio of 1.32. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a better Quick ratio (1.32) than 65.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
The earnings per share for DC4 have decreased by -0.60% in the last year.
The Earnings Per Share has been growing by 29.25% on average over the past years. This is a very strong growth
DC4 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.11%.
DC4 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.27% yearly.
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
3.2 Future
DC4 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.56% yearly.
Based on estimates for the next years, DC4 will show a quite strong growth in Revenue. The Revenue will grow by 14.01% on average per year.
EPS Next Y25.42%
EPS Next 2Y25.27%
EPS Next 3Y24.56%
EPS Next 5Y22.56%
Revenue Next Year14.72%
Revenue Next 2Y15%
Revenue Next 3Y14.87%
Revenue Next 5Y14.01%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 52.46, which means the current valuation is very expensive for DC4.
The rest of the industry has a similar Price/Earnings ratio as DC4.
DC4's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.15.
With a Price/Forward Earnings ratio of 33.48, DC4 can be considered very expensive at the moment.
DC4's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.60, DC4 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.46 | ||
| Fwd PE | 33.48 |
4.2 Price Multiples
DC4's Enterprise Value to EBITDA ratio is in line with the industry average.
DC4's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.1 | ||
| EV/EBITDA | 35.11 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DC4 has an outstanding profitability rating, which may justify a higher PE ratio.
DC4's earnings are expected to grow with 24.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.06
PEG (5Y)1.79
EPS Next 2Y25.27%
EPS Next 3Y24.56%
5. Dividend
5.1 Amount
DC4 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:DC4 (6/27/2025, 7:00:00 PM)
73.97
-0.16 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.23%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap29.00B
Analysts85.45
Price Target88.83 (20.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.87%
Min EPS beat(2)-11.66%
Max EPS beat(2)-4.09%
EPS beat(4)2
Avg EPS beat(4)-1.25%
Min EPS beat(4)-11.66%
Max EPS beat(4)9.24%
EPS beat(8)6
Avg EPS beat(8)14.5%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)12.29%
Revenue beat(2)0
Avg Revenue beat(2)-0.7%
Min Revenue beat(2)-1.2%
Max Revenue beat(2)-0.19%
Revenue beat(4)0
Avg Revenue beat(4)-2.01%
Min Revenue beat(4)-4.99%
Max Revenue beat(4)-0.19%
Revenue beat(8)2
Avg Revenue beat(8)-0.7%
Revenue beat(12)4
Avg Revenue beat(12)-0.65%
Revenue beat(16)6
Avg Revenue beat(16)-0.11%
PT rev (1m)-1.37%
PT rev (3m)-10.58%
EPS NQ rev (1m)-0.79%
EPS NQ rev (3m)-6.29%
EPS NY rev (1m)0.11%
EPS NY rev (3m)0.58%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)-0.35%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.46 | ||
| Fwd PE | 33.48 | ||
| P/S | 8.2 | ||
| P/FCF | 59.1 | ||
| P/OCF | 35.26 | ||
| P/B | 15 | ||
| P/tB | 15.82 | ||
| EV/EBITDA | 35.11 |
EPS(TTM)1.41
EY1.91%
EPS(NY)2.21
Fwd EY2.99%
FCF(TTM)1.25
FCFY1.69%
OCF(TTM)2.1
OCFY2.84%
SpS9.03
BVpS4.93
TBVpS4.67
PEG (NY)2.06
PEG (5Y)1.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.93% | ||
| ROE | 23.61% | ||
| ROCE | 18.47% | ||
| ROIC | 14.54% | ||
| ROICexc | 53.32% | ||
| ROICexgc | 60.37% | ||
| OM | 16.54% | ||
| PM (TTM) | 12.9% | ||
| GM | 60.72% | ||
| FCFM | 13.87% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 1.42 | ||
| Cap/Depr | 172.69% | ||
| Cap/Sales | 9.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.79% | ||
| Profit Quality | 107.47% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z | 6.12 |
F-Score6
WACC8.25%
ROIC/WACC1.76
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.6%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%0%
EPS Next Y25.42%
EPS Next 2Y25.27%
EPS Next 3Y24.56%
EPS Next 5Y22.56%
Revenue 1Y (TTM)9.11%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%12.49%
Revenue Next Year14.72%
Revenue Next 2Y15%
Revenue Next 3Y14.87%
Revenue Next 5Y14.01%
EBIT growth 1Y2.68%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.08%
EBIT Next 3Y38.17%
EBIT Next 5Y31.52%
FCF growth 1Y38.27%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y27.88%
OCF growth 3Y30.77%
OCF growth 5Y25.76%